Omacetaxine
T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
48 Active assets in the T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Children's Oncology Group | Phase 3 | BB |
Cytosin-Arabinosid Princess Maxima Center for Pediatric Oncology | Phase 3 | BB |
Cyclophosphamide Children's Oncology Group | Phase 3 | BB |
ETOPOSIDE Children's Cancer Group, China | Phase 3 | BB |
Daunorubicin Children's Oncology Group | Phase 3 | B |
View all 50 →
Same molecule, other indications
Omacetaxine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →